The aim of this study is to assess the projected incidence and prognostic indicators of gynecologic malignancies in the pediatric population. In this population-based retrospective cohort study, girls ≤18 years with ovarian, uterine, cervical, vaginal and vulvar malignancies diagnosed between 2000 and 2016 were identified from the Surveillance, Epidemiology and End Results (SEER)-18 registry. The Kaplan-Meier method was used to analyze overall survival (OS). The age-adjusted annual incidence of gynecologic malignancies was 6.7 per 1,000,000 females, with neoplasms of the ovary accounting for 87.5%, vagina 4.5%, cervix 3.9%, uterus 2.5% and vulva 1.6% of all gynecologic malignancies. Malignant germ-cell tumors represented the most common ovarian neoplasm, with an increased incidence in children from 5-18 years. Although certain subtypes were associated with advanced disease stages, the 10-year OS rate was 96.0%. Sarcomas accounted for the majority of vaginal, cervical, uterine and vulvar malignancies. The majority of vaginal neoplasms were observed in girls between 0-4 years, and the 10-year OS rate was 86.1%. Overall, gynecologic malignancies accounted for 4.2% of all malignancies in girls aged 0-18 years and the histologic subtypes and prognosis differed significantly from patients in older age groups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918615PMC
http://dx.doi.org/10.3390/jcm10040722DOI Listing

Publication Analysis

Top Keywords

gynecologic malignancies
20
vulvar malignancies
8
10-year rate
8
majority vaginal
8
malignancies
7
gynecologic
5
malignancies children
4
children adolescents
4
adolescents common
4
common uncommon?
4

Similar Publications

Purpose: Artificial Intelligence models based on medical (imaging) data are increasingly developed. However, the imaging software on which the original data is generated is frequently updated. The impact of updated imaging software on the performance of AI models is unclear.

View Article and Find Full Text PDF

Ovarian sex cord-stromal tumors (SCST) are a rare subset of ovarian neoplasms originating from supportive tissues surrounding oocytes. Despite their rarity, prompt diagnosis and management are crucial due to their potential for diverse clinical presentations and the need to optimize patient outcomes. A 25-year-old female patient was initially diagnosed with pyelonephritis but later discovered to have a large right adnexal mass suspected to be a tubo-ovarian abscess.

View Article and Find Full Text PDF

Background: The increase in survival rates among women treated for cervical cancer (CC) requires greater attention to the side effects of treatment. Although a high prevalence of pelvic floor disorders (PFD) in this population is documented, there is a lack of consensus regarding physical therapy approaches.

Methods: Cross-sectional observational study with 56 physiotherapists who answered a questionnaire.

View Article and Find Full Text PDF

N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential.

J Hematol Oncol

January 2025

Department of Gynecology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

N7-methylguanosine (m7G) is an important RNA modification involved in epigenetic regulation that is commonly observed in both prokaryotic and eukaryotic organisms. Their influence on the synthesis and processing of messenger RNA, ribosomal RNA, and transfer RNA allows m7G modifications to affect diverse cellular, physiological, and pathological processes. m7G modifications are pivotal in human diseases, particularly cancer progression.

View Article and Find Full Text PDF

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey.

BMC Cancer

January 2025

Young Academy of Gynecologic Oncology (JAGO), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany.

Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!